Post
Interim analysis of APPLAUSE-IgAN trial sheds positive light on Fabhalta for IgAN
At this year’s World Congress of Nephrology, positive results were presented from Novartis’s pre-specified interim analysis of the Phase III …
Krystal Biotech doses first subject in lung cancer drug trial
US-based biotechnology company Krystal Biotech has dosed the first subject in the Phase I KYANITE-1 clinical trial for its inhaled …
ASLAN reports interim data from atopic dermatitis drug trial
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug …
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune …
Actinogen finishes enrolling patients in depression therapy trial
Australian biotechnology company Actinogen Medical has finished enrolling subjects in the Phase IIa XanaCIDD clinical trial of Xanamem for treating …
Lantern Pharma cleared to expand lung cancer treatment trial
US-based biopharmaceutical company Lantern Pharma has received regulatory approval for expanding its Phase II Harmonic clinical trial of an investigational …
PPD affects races similarly, inequities lie in mental healthcare
Postpartum depression (PPD) is depression lasting more than two weeks postpartum, and is characterised by feelings of hopelessness, anger, guilt, …
AAN 2024: Monitoring adverse events associated with gene transfer therapies
At the American Academy of Neurology (AAN) 2024 Annual Meeting, during the Neurology Year in Review Plenary Session, the safety …
How can clinical trial outsourcing and operations be optimised?
With the intention of discovering effective and budget-friendly outsourcing strategies for smooth clinical trial operations, industry leaders and keynote speakers …
Q&A: Bring your own device: How patients own tech is being used in clinical trials
Keeping track of your pulse, heart rate and oxygen saturation has never been easier, with smartwatches able to easily track …
Ocugen completes dosing in second cohort of OCU410 geographic atrophy trial
Biotechnology company Ocugen has completed dosing in the second cohort of its Phase I/II ArMaDa clinical trial of modifier gene therapy …
ACTG begins trial of three immune-based therapy combinations for HIV cure
ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a combination …
Inozyme to run Phase III trial of INZ-701 in paediatric ABCC6 deficiency
Inozyme Pharma is speaking to the US Food and Drug Administration (FDA) about running a Phase III trial of INZ-701 …
Nexsen lays out clinical plans for rapid Strep B test development
Nexsen Biotech plans to evaluate the sensitivity and specificity of its rapid point of care for Group B streptococci (GBS), …
FDA approves Phase III trial of GenFleet’s KRAS G12C inhibitor
The US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics’ Phase III clinical trial of GFH925, a …